Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
Brevinor 0.5 milligram (mg)/35 micrograms (μg) Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Blue, flat, circular, bevel-edged tablet inscribed ‘SEARLE’ on one side and ‘BX’ on the other side. |
Each tablet contains 0.5 milligrams norethisterone and 35 micrograms ethinylestradiol.
Excipients with known effect:
Each tablet contains lactose.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| 17 alpha-Ethinylestradiol |
Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy. |
|
| Norethisterone |
Norethisterone has progestational actions similar to those of progesterone, but is a more potent inhibitor of ovulation and has weak oestrogenic and androgenic properties. It is used to treat a number of disorders of the menstrual cycle. |
| List of Excipients |
|---|
|
Maize starch |
Pvc/foil blister packs of 21 and 63 tablets. Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK
PL 00057/0935
27 June 2002
| Drug | Countries | |
|---|---|---|
| BREVINOR | Australia, New Zealand, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
